Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin-In Reply
JAMA Oncol
.
2019 Jun 1;5(6):911-912.
doi: 10.1001/jamaoncol.2019.0630.
Authors
Tracey G Simon
1
2
3
,
Andrew T Chan
1
2
3
4
5
6
Affiliations
1
Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston.
2
Harvard Medical School, Boston, Massachusetts.
3
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston.
4
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston Massachusetts.
5
Broad Institute, Boston Massachusetts.
6
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston Massachusetts.
PMID:
31046066
DOI:
10.1001/jamaoncol.2019.0630
No abstract available
Publication types
Comment
MeSH terms
Aspirin
Carcinoma, Hepatocellular*
Humans
Liver Neoplasms*
Risk Assessment
Risk Factors
Substances
Aspirin